OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update
July 08, 2022 07:30 ET
|
OpGen, Inc.
Preliminary Total Revenue for Q2 2022 was approximately $1.0 millionCash as of June 30, 2022 was approximately $16.6 millionFirst commercial customer contract for Acuitas AMR Gene Panel signed in June...
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients
June 22, 2022 08:00 ET
|
OpGen, Inc.
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of pathogens by Unyvero HPNAdditional pathogens...
OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel
June 22, 2022 07:30 ET
|
OpGen, Inc.
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for different sample types and accelerate trial...
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar
June 09, 2022 07:30 ET
|
OpGen, Inc.
Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term Leader Life Sciences to seek regulatory...
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine
May 26, 2022 07:30 ET
|
OpGen, Inc.
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic...
OpGen Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:15 ET
|
OpGen, Inc.
Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., May ...
OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time
April 28, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment
April 25, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., April 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
April 20, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., April 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
April 06, 2022 07:30 ET
|
OpGen, Inc.
Extended existing master services agreement with Sandoz, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening focus on...